Biogen Inc. (NASDAQ:BIIB) shares climbed 3.04% to 216.12 dollars on the day, as investors weighed the biotech's turnaround from years of declining multiple sclerosis drug sales against a fresh wave of dealmaking meant to diversify its business.
| Price | 216.12 USD |
|---|---|
| Day change | +6.38 (+3.04%) |
| 52-week range | 175.69 – 219.72 |
| Market cap | $31.91B |
| P/E ratio | 23.11 |
| EPS (ttm) | 9.35 |
| RSI (14) | 64.82 |
| Volume | 1,155,165 |
Why Biogen Stock Is Moving
The company built its name on multiple sclerosis treatments like Tecfidera and Tysabri, but patent expirations have hit those franchises hard. Tecfidera alone fell from 4.4 billion dollars in peak sales back in 2019 to just 1.4 billion dollars by 2022. Last fiscal year, all of Biogen's MS drugs combined brought in 4 billion dollars, a fraction of what the franchise once generated on its own.
Chief executive Christopher Viehbacher told investors during the most recent quarter that after four straight years of earnings declines starting in 2023, Biogen has finally managed to stabilize the business. Newer growth products, including the Alzheimer's treatment Leqembi, the Friedreich ataxia drug Skyclarys, and the postpartum depression medicine Zurzuvae, posted a combined 12% sales increase to 850 million dollars in the first quarter, with each drug logging double or triple digit growth.
Acquisitions Reshaping the Portfolio
Biogen has leaned on acquisitions to push into immunology alongside its neurology roots. It announced plans in March to buy Apellis Pharmaceuticals, closing the deal in May. That purchase brought two commercialized drugs into the fold: Empaveli, used across three indications including two rare kidney diseases, and Syfovre, for an immune mediated retinal disease. Together those two products generated 689 million dollars in sales last year. More recently, Biogen agreed to pay 1 billion dollars for another company whose product lineup has not been disclosed publicly, a deal that adds to the sense the company is actively reshaping where its future revenue will come from.
Biogen Valuation, Momentum and Yield
Biogen trades at a price to earnings ratio of 23.11, with a market capitalization of 31.91 billion dollars. Shares sit near the top of their 52 week range of 175.69 to 219.72 dollars, and a relative strength index of 64.82 suggests buying interest has been steady without yet tipping into clearly overbought territory.
The bull case rests on the stabilization Viehbacher described: growth drugs are expanding fast enough to offset the ongoing decline in legacy MS revenue, and the Apellis and undisclosed acquisitions add new commercial products rather than just pipeline hopes. The bear case centers on execution risk. Biogen is still absorbing two acquisitions at once, integration costs and debt from the 1 billion dollar deal could pressure margins, and the company does not currently pay a dividend, meaning shareholders are betting entirely on price appreciation tied to a turnaround that remains in its early stages.